1887

Abstract

eradication remains a challenge for physicians. Sequential, concomitant and the hybrid regimens have been proposed as novel, more effective therapies. We compare the efficacy of these therapies. Dyspeptic patients referred for upper endoscopy with infection were enrolled. Patients were randomized to receive: (a) sequential therapy – 20 mg omeprazole and 1 g amoxicillin for 5 days, followed by 20 mg omeprazole, 500 mg clarithromycin and 500 mg tinidazole for the successive 5 days; (b) concomitant therapy – 20 mg omeprazole, 1 g amoxicillin, 500 mg clarithromycin and 500 mg tinidazole for either 5 days (5 day concomitant) or 14 days (14 day concomitant); or (c) hybrid therapy – 20 mg omeprazole and 1 g amoxicillin for 7 days, followed by 20 mg omeprazole, 1 g amoxicillin, 500 mg clarithromycin and 500 mg tinidazole for the successive 7 days. All drugs were given twice daily. Bacterial eradication was checked by using a [C]urea breath test. In ‘intention-to-treat’ analysis, sequential therapy achieved the highest eradication rate, which was higher than that of 5 day concomitant therapy (90  vs 78.1 %;  = 0.02). The success rate did not statistically differ among the sequential and either 14 day concomitant (90  vs 86.3 %;  = not significant) or hybrid therapies (90  vs 82.7 %;  = not significant). The 10 day sequential, 14 day concomitant and 14 day hybrid therapies, but not the 5 day concomitant regimen, achieved similarly high eradication rates. The lower therapeutic cost coupled with the lower number of tablets needed would favour the sequential therapy as the first-line treatment in clinical practice.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.072322-0
2014-05-01
2019-10-23
Loading full text...

Full text loading...

/deliver/fulltext/jmm/63/5/748.html?itemId=/content/journal/jmm/10.1099/jmm.0.072322-0&mimeType=html&fmt=ahah

References

  1. Alakkari A., Zullo A., O’Connor H. J.. ( 2011;). Helicobacter pylori and nonmalignant diseases. . Helicobacter 16: (Suppl. 1), 33–37. [CrossRef][PubMed]
    [Google Scholar]
  2. Caselli M., Zullo A., Maconi G., Parente F., Alvisi V., Casetti T., Sorrentino D., Gasbarrini G..Working Group of the Cervia II Meeting ( 2007;). “Cervia II Working Group Report 2006”: guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy. . Dig Liver Dis 39:, 782–789. [CrossRef][PubMed]
    [Google Scholar]
  3. De Francesco V., Zullo A., Hassan C., Della Valle N., Pietrini L., Minenna M. F., Winn S., Monno R., Stoppino V.. & other authors ( 2004;). The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study. . Dig Liver Dis 36:, 322–326. [CrossRef][PubMed]
    [Google Scholar]
  4. De Francesco V. D., Zullo A., Hassan C., Giorgio F., Rosania R., Ierardi E.. ( 2011;). Mechanisms of Helicobacter pylori antibiotic resistance: an updated appraisal. . World J Gastrointest Pathophysiol 2:, 35–41. [CrossRef][PubMed]
    [Google Scholar]
  5. De Francesco V., Ierardi E., Hassan C., Zullo A.. ( 2012;). Helicobacter pylori therapy: present and future. . World J Gastrointest Pharmacol Ther 3:, 68–73. [CrossRef][PubMed]
    [Google Scholar]
  6. Essa A. S., Kramer J. R., Graham D. Y., Treiber G.. ( 2009;). Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing “concomitant therapy” versus triple therapy for Helicobacter pylori eradication. . Helicobacter 14:, 109–118. [CrossRef][PubMed]
    [Google Scholar]
  7. Fuccio L., Minardi M. E., Zagari R. M., Grilli D., Magrini N., Bazzoli F.. ( 2007;). Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. . Ann Intern Med 147:, 553–562. [CrossRef][PubMed]
    [Google Scholar]
  8. Gisbert J. P., Calvet X.. ( 2011;). Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. . Aliment Pharmacol Ther 34:, 1255–1268. [CrossRef][PubMed]
    [Google Scholar]
  9. Gisbert J. P., Calvet X.. ( 2012;). Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori.. Clin Exp Gastroenterol 5:, 23–34. [CrossRef][PubMed]
    [Google Scholar]
  10. Graham D. Y., Fischbach L.. ( 2010;). Helicobacter pylori treatment in the era of increasing antibiotic resistance. . Gut 59:, 1143–1153. [CrossRef][PubMed]
    [Google Scholar]
  11. Hsu P. I., Wu D. C., Wu J. Y., Graham D. Y.. ( 2011;). Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. . Helicobacter 16:, 139–145. [CrossRef][PubMed]
    [Google Scholar]
  12. Kongchayanun C., Vilaichone R. K., Pornthisarn B., Amornsawadwattana S., Mahachai V.. ( 2012;). Pilot studies to identify the optimum duration of concomitant Helicobacter pylori eradication therapy in Thailand. . Helicobacter 17:, 282–285. [CrossRef][PubMed]
    [Google Scholar]
  13. Lim J. H., Lee D. H., Choi C., Lee S. T., Kim N., Jeong S. H., Kim J. W., Hwang J. H., Park Y. S.. & other authors ( 2013;). Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study. . Helicobacter 18:, 180–186. [CrossRef][PubMed]
    [Google Scholar]
  14. McNicholl A. G., Gisbert J. P.. ( 2012;). Commentary: comparators in H. pylori eradication – stating the ethics of statins. . Aliment Pharmacol Ther 36:, 400–401. [CrossRef][PubMed]
    [Google Scholar]
  15. McNicholl A. G., Marin A. C., Molina-Infante J., Castro M., Barrio J., Ducons J., Calvet X., de la Coba C., Montoro M.. & other authors ( 2014;). Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. . Gut 63:, 244–249. [CrossRef][PubMed]
    [Google Scholar]
  16. Nagahara A., Miwa H., Ogawa K., Kurosawa A., Ohkura R., Iida N., Sato N.. ( 2000;). Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy. . Helicobacter 5:, 88–93. [CrossRef][PubMed]
    [Google Scholar]
  17. Nagahara A., Miwa H., Yamada T., Kurosawa A., Ohkura R., Sato N.. ( 2001;). Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. . Aliment Pharmacol Ther 15:, 417–421. [CrossRef][PubMed]
    [Google Scholar]
  18. Okada M., Oki K., Shirotani T., Seo M., Okabe N., Maeda K., Nishimura H., Ohkuma K., Oda K.. ( 1998;). A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate. . J Gastroenterol 33:, 640–645. [CrossRef][PubMed]
    [Google Scholar]
  19. Saracino I. M., Zullo A., Holton J., Castelli V., Fiorini G., Zaccaro C., Ridola L., Ricci C., Gatta L., Vaira D.. ( 2012;). High prevalence of primary antibiotic resistance in Helicobacter pylori isolates in Italy. . J Gastrointestin Liver Dis 21:, 363–365.[PubMed]
    [Google Scholar]
  20. Treiber G., Ammon S., Schneider E., Klotz U.. ( 1998;). Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. . Helicobacter 3:, 54–58. [CrossRef][PubMed]
    [Google Scholar]
  21. Treiber G., Wittig J., Ammon S., Walker S., van Doorn L. J., Klotz U.. ( 2002;). Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). . Arch Intern Med 162:, 153–160. [CrossRef][PubMed]
    [Google Scholar]
  22. Zullo A., Rinaldi V., Winn S., Meddi P., Lionetti R., Hassan C., Ripani C., Tomaselli G., Attili A. F.. ( 2000;). A new highly effective short-term therapy schedule for Helicobacter pylori eradication. . Aliment Pharmacol Ther 14:, 715–718. [CrossRef][PubMed]
    [Google Scholar]
  23. Zullo A., De Francesco V., Hassan C., Morini S., Vaira D.. ( 2007;). The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. . Gut 56:, 1353–1357. [CrossRef][PubMed]
    [Google Scholar]
  24. Zullo A., De Francesco V., Manes G., Scaccianoce G., Cristofari F., Hassan C.. ( 2010;). Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice. . J Gastrointestin Liver Dis 19:, 131–134.[PubMed]
    [Google Scholar]
  25. Zullo A., Scaccianoce G., De Francesco V., Ruggiero V., D’Ambrosio P., Castorani L., Bonfrate L., Vannella L., Hassan C., Portincasa P.. ( 2013a;). Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study. . Clin Res Hepatol Gastroenterol 37:, 647–650. [CrossRef][PubMed]
    [Google Scholar]
  26. Zullo A., Hassan C., Ridola L., De Francesco V., Vaira D.. ( 2013b;). Standard triple and sequential therapies for Helicobacter pylori eradication: an update. . Eur J Intern Med 24:, 16–19. [CrossRef][PubMed]
    [Google Scholar]
  27. Zullo A., De Francesco V., Hassan C., Ridola L., Repici A., Bruzzese V., Vaira D.. ( 2013c;). Modified sequential therapy regimens for Helicobacter pylori eradication: a systematic review. . Dig Liver Dis 45:, 18–22. [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.072322-0
Loading
/content/journal/jmm/10.1099/jmm.0.072322-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error